The wider accessibility of SPECT scanners, recent progress in the development of the new generation of SPECT cameras, low costs of SPECT investigation, and the spread of PCa in the population all support the further development of GRPR imaging agents for SPECT. This evidence concerns the gene GRPR and posterior cortical atrophy.